KLS-2031

N/A

Report date: 2025/03/26 20:01:25

Base Information

Drug NameKLS-2031
Drug Alias NameKLS-2031
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionGlial cell line-derived neurotrophic factors stimulantsInterleukin-10 stimulantsGlutamate decarboxylase 2 stimulants
TargetsGlial cell line-derived neurotrophic factor receptorsInterleukin-10Glutamate decarboxylase 2
Therapy Area/IndicationsRadiculopathyNeuralgia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesKolon Life Science. Inc
China Registration ClassN/A

Develop Information

Active CompaniesKolon Life Science. Inc
Inactive CompaniesN/A
Active IndicationsRadiculopathyNeuralgia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A